dc.contributor.author |
Hobololo, Vuyisile
|
|
dc.date.accessioned |
2016-01-18T17:20:20Z |
|
dc.date.available |
2016-01-18T17:20:20Z |
|
dc.date.issued |
2015-12-15 |
|
dc.identifier.citation |
Hobololo, V. (2015). Strategic patenting of pharmaceutical inventions and the public’s right to access medicines: The South African context. The African Journal of Information and Communication (AJIC), 16, 78-81. https://doi.org/10.23962/10539/19317 |
en_ZA |
dc.identifier.issn |
ISSN 2077-7213 (online version) |
|
dc.identifier.issn |
ISSN 2077-7205 (print version) |
|
dc.identifier.uri |
http://hdl.handle.net/10539/19317 |
|
dc.identifier.uri |
https://doi.org/10.23962/10539/19317 |
|
dc.description.abstract |
Pharmaceutical firms’ use of strategic patenting to influence the markets within which their patented inventions sit is legally questionable. Such
patenting entails filing patents with the intention of blocking potential competitors from innovating and/or being granted patents within niche
technology areas of interest to the patentee. Under this practice, patentees are potentially able to extend the breadth and duration of their
monopoly power in the pharmaceutical market sub-sector within which that invention sits. Such practices take on a clear public interest element
if they undermine affordable public access to medicines. This thematic report outlines forms of strategic patenting, analyses the degree to which
the South African legal system provides remedies against such patenting, and proposes ways forward for South Africa to prevent such practices. |
en_ZA |
dc.language.iso |
en |
en_ZA |
dc.subject |
patents, pharmaceuticals, strategic patenting, public interest, access, compulsory licensing, competition, South Africa |
en_ZA |
dc.title |
Strategic Patenting of Pharmaceutical Inventions and the Public’s Right to Access Medicines: The South African Context |
en_ZA |
dc.type |
Article |
en_ZA |
ddi.method |
policy review |
|
dc.citation.doi |
https://doi.org/10.23962/10539/19317 |
|